Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe
Kitty J. Jager(Amsterdam University Medical Centers), Ziad A. Massy(Inserm), Patrice M. Ambühl(Triemli Hospital), Anneke Kramer(Amsterdam University Medical Centers), Christoph Wanner(Universitätsklinikum Würzburg), J. Emilio Sánchez-Álvarez(Hospital Universitario De Cabueñes), Marc H. Hemmelder(Nefrovisie), Julia Kerschbaum(Statistics Austria), Lionel Mazzoleni(CHU Ambroise Paré), María Dolores del Pino y Pino(Complejo Hospitalario Torrecárdenas), Rebecca Winzeler(Triemli Hospital), Liliana Gârneaţă(Carol Davila University of Medicine and Pharmacy), Carmine Zoccali(Biogem), Vianda S Stel(Amsterdam UMC Location University of Amsterdam), Camille Legeai(Agence de la Biomédecine), Gabriel Mircescu(Carol Davila University of Medicine and Pharmacy), Cécile Couchoud(Agence de la Biomédecine), Tiny Hoekstra(Nefrovisie), Frédéric Collart(French Community of Belgium), Gert Mayer(Statistics Austria), Nicholas C Chesnaye(Amsterdam Neuroscience)
Cited by 502
Related Papers
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
|American Journal of Nephrology|2017|2.2k
Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study
|The Lancet|2001|1.1k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990